Table 1.
Phase II Trials of Multikinase Inhibitors in Advanced DTC
| Drug | Targets | First Author, Year (Ref.) | n | RECIST Progressivea | PFS, mo | Discontinued drug (AE)b |
|---|---|---|---|---|---|---|
| Gefitinib | EGFR | Pennell, 2008 (112) | 17 | No | 3.9 | 7% |
| Axitinib | VEGFR, PDGFR, c-Kit | Cohen, 2008 (56) | 60 | No | 18.1 | 13% |
| Sorafenib | BRAF, VEGFR, PDGFR, RET | Gupta, 2008 (3) | 30 | Noc | 18.4 | 17% |
| Kloos, 2009 (4) | 41 | No | 15.0 | 26% | ||
| Hoftijzer, 2009 (5) | 31 | Yes | 13.4 | 19% | ||
| Ahmed, 2011 (49) | 34 | No | >19.0 | 6% | ||
| Motesanib | VEGFR, PDGFR, c-Kit | Sherman, 2008 (48) | 93 | Yes | 9.3 | 13% |
| Sunitinib | PDGFR, FLT3, c-Kit, VEGFR | Carr, 2010 (113) | 28 | No | 12.8 | 11% |
| Pazopanib | VEGFR, PDGFR, c-Kit | Bible, 2010 (52) | 37 | Yes | 11.4 | 5% |
a
Required RECIST progressive disease for enrollment.
b
Percentage of patients discontinuing drug due to AEs.
c
All had progressive disease.